Hologic Toekomstige groei

Future criteriumcontroles 1/6

Hologic zal naar verwachting groeien in winst en omzet met respectievelijk 9.2% en 4.9% per jaar. De winst per aandeel zal naar verwachting groeien met 10.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 17.6% zijn.

Belangrijke informatie

9.2%

Groei van de winst

10.9%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.7%
Inkomstengroei	4.9%
Toekomstig rendement op eigen vermogen	17.6%
Dekking van analisten	Good
Laatst bijgewerkt	06 Nov 2024

Recente toekomstige groei-updates

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Feb 06

Recent updates

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Jun 20

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

May 22

Hologic: Women's Health Play Looks Healthier Itself

May 13

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Apr 19

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Apr 05

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Mar 20

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Feb 22

Hologic: Prospects For Growth As Headwinds Disappear

Feb 11

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Feb 09

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Feb 06

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Jan 29

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Dec 30

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Dec 11

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Nov 08

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Oct 25

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Sep 28

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Aug 29

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Jul 31

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Jul 18

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Jun 21

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

May 22

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Apr 25

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Apr 10

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher

Mar 13

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Feb 14

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Jan 18

Winst- en omzetgroeiprognoses

NasdaqGS:HOLX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2027	4,672	1,004	1,227	1,218	8
9/30/2026	4,437	923	1,155	1,209	16
9/30/2025	4,181	834	1,002	1,095	15
9/30/2024	4,020	803	1,007	1,070	18
6/29/2024	3,988	702	1,015	1,177	N/A
3/30/2024	3,961	467	949	1,104	N/A
12/30/2023	3,969	515	859	1,018	N/A
9/30/2023	4,030	456	901	1,051	N/A
7/1/2023	4,038	484	832	961	N/A
4/1/2023	4,057	753	841	959	N/A
12/31/2022	4,466	990	1,696	1,815	N/A
9/24/2022	4,863	1,302	1,999	2,126	N/A
6/25/2022	5,226	1,512	2,283	2,423	N/A
3/26/2022	5,392	1,552	2,598	2,755	N/A
12/25/2021	5,494	1,716	2,068	2,245	N/A
9/25/2021	5,632	1,872	2,146	2,330	N/A
6/26/2021	5,663	2,038	2,108	2,307	N/A
3/27/2021	5,317	1,907	1,677	1,867	N/A
12/26/2020	4,536	1,384	1,263	1,433	N/A
9/26/2020	3,776	1,115	740	897	N/A
6/27/2020	3,295	497	573	702	N/A
3/28/2020	3,325	453	518	643	N/A
12/28/2019	3,387	84	536	659	N/A
9/28/2019	3,367	-204	536	650	N/A
6/29/2019	3,315	-30	520	634	N/A
3/30/2019	3,287	-11	596	705	N/A
12/29/2018	3,258	-419	562	668	N/A
9/29/2018	3,218	-111	627	733	N/A
6/30/2018	3,207	-79	560	667	N/A
3/31/2018	3,189	-132	N/A	21	N/A
12/30/2017	3,116	1,076	N/A	8	N/A
9/30/2017	3,059	756	N/A	8	N/A
7/1/2017	2,983	765	N/A	70	N/A
4/1/2017	2,894	790	N/A	729	N/A
12/31/2016	2,872	332	N/A	796	N/A
9/24/2016	2,833	331	N/A	798	N/A
6/25/2016	2,809	264	N/A	802	N/A
3/26/2016	2,785	208	N/A	797	N/A
12/26/2015	2,747	187	N/A	804	N/A
9/26/2015	2,705	132	N/A	797	N/A
6/27/2015	2,641	135	N/A	685	N/A
3/28/2015	2,580	116	N/A	601	N/A
12/27/2014	2,549	52	N/A	513	N/A
9/27/2014	2,531	17	N/A	508	N/A
6/28/2014	2,477	-1,125	N/A	455	N/A
3/29/2014	2,470	-1,147	N/A	543	N/A
12/28/2013	2,458	-1,181	N/A	488	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei HOLX ( 9.2% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van HOLX ( 9.2% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.6% per jaar).

Hoge groeiwinsten: De winst van HOLX zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van HOLX ( 4.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van HOLX ( 4.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen HOLX zal naar verwachting over 3 jaar laag zijn ( 17.6 %).

Hologic Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year of 2025

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Recent updates

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year of 2025

When Should You Buy Hologic, Inc. (NASDAQ:HOLX)?

Hologic: Continued Room Amidst Bolt-On M&A Efforts

Hologic (NASDAQ:HOLX) Seems To Use Debt Rather Sparingly

Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million.

Hologic, Inc. to Report Q4, 2024 Results on Nov 04, 2024

Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares.

Hologic, Inc. (NASDAQ:HOLX) Not Flying Under The Radar

Chief Financial Officer notifies of intention to sell stock

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Chairman notifies of intention to sell stock

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million.

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Hologic: Women's Health Play Looks Healthier Itself

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Now 20% undervalued

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Independent Director notifies of intention to sell stock

Now 20% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Now 20% undervalued

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic: Prospects For Growth As Headwinds Disappear

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Now 21% undervalued

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Now 21% undervalued

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Independent Director notifies of intention to sell stock

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Chairman exercised options and sold US$2.1m worth of stock

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Full year 2023 earnings: EPS misses analyst expectations

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Consensus EPS estimates fall by 22%

Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt